The role of cytokines in the pathophysiology of chronic liver diseases

  • Herbert Tign
Reviews

Summary

Many of the biological activities of cytokines are similar to clinical manifestations and abnormalities of laboratory parameters observed in chronic liver diseases (CLD). Evidence of impaired cytokine synthesis in CLD comes from studies of serum or plasma levels, supernatants of peripheral blood mononuclear cells stimulated with various agents and from studying cytokine expression locally in the liver. Circulating levels of several cytokine-regulated molecules such as neopterin, soluble IL-2 receptor, adhesion molecules, and metabolites of the nitric oxide pathway are elevated in patients with CLD. Thus inhibition of cytokine synthesis or modulation of their activity could provide not only important information about their pathophysiologic relevance but also have a profound impact on disease progression in CLD. These studies will also show whether prolonged anti-cytokine treatment with interleukin-1- or tumor necrosis factor-inhibitors interferes with host defense mechanism.

Key words

Cytokines Liver diseases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams DH, Mainolfi E, Burra P, et al, Detection of circulating intercellular adhesion molecule-1 in chronic liver disease. Hepatology 16: 810, 1992PubMedCrossRefGoogle Scholar
  2. 2.
    Anastassakos C, Alexander GJ, Wolstencraft RA, et al, Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology 94: 999, 1988PubMedGoogle Scholar
  3. 3.
    Andus T, Bauer J, Gerok W, Effects of cytokines on the liver. Hepatology 13: 364, 1991PubMedGoogle Scholar
  4. 4.
    Arend WP, Interleukin-1 receptor antagonist. J Clin Invest 88: 1445, 1991PubMedGoogle Scholar
  5. 5.
    Ashkenazi A, Marsters SA, Capon DJ, et al, Protection against endotoxic shock by a human tumor necrosis factor receptor immunoadhesion. Proc Natl Acad Sci USA 88: 10535, 1991PubMedCrossRefGoogle Scholar
  6. 6.
    Bemelmanns MHA, Gouma DJ, Greve JW, et al., Cytokines tumor, necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 15:1132, 1992CrossRefGoogle Scholar
  7. 7.
    Billiau A, Matthys P, Interferon-gamma, more of a cachectin than tumor necrosis factor. Cytokine 4:259, 1992.PubMedCrossRefGoogle Scholar
  8. 8.
    Bissel DM, Roll J, Connective tissue metabolism and hepatic fibrosis. In: Zakim D, Boyer TD (eds) Hepatology 2nd edn. Saunders, Philadelphia, 1990.Google Scholar
  9. 9.
    Ceretti DP, Kozlovsky CJ, Mosley B, et al., Molecular cloning of the interleukin-1β converting enzyme. Science 256:97, 1992CrossRefGoogle Scholar
  10. 10.
    Cobb JP, Natanson C, Hoffman WD, et al., N-Amino-L-Arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 175:1175, 1992CrossRefGoogle Scholar
  11. 11.
    Czaja MJ, Flanders KC, Biempica L, et al., Expression of tumor necrosis factor-α and transforming growth factor-β in acute liver injury. Growth Factors 1:219, 1989PubMedGoogle Scholar
  12. 12.
    Daito K, Suou T, Kawasaki H, Clinical significance of serum and urinary neopterin levels in patients with various liver diseases. Am J Gastroenterol 87:471, 1992PubMedGoogle Scholar
  13. 13.
    Deviere J, Content J, Denys C, et al., High interleukin-6 serum levels and increased production by leukocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokine production. Clin Exp Immunol 77:221, 1989PubMedGoogle Scholar
  14. 14.
    Deviere J, Content J, Denys C, et al., Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 11:628, 1990PubMedCrossRefGoogle Scholar
  15. 15.
    Dinarello CA, Interleukin-1 and interleukin-1 antagonism. Blood 77:1627, 1991PubMedGoogle Scholar
  16. 16.
    Dinarello CA, Thompson RC, Blocking IL-1 interleukin-1 receptor antagonist in vitro and in vivo. Immunol Today 12:404, 1991PubMedCrossRefGoogle Scholar
  17. 17.
    Dinarello CA, Wolff SM, The role of interleukin-1 in diesease. N Engl J Med 328:106, 1993PubMedCrossRefGoogle Scholar
  18. 18.
    Dufour JF, Arias IM, Nitric oxide inhibits bile canalicular contraction: a potential cholestatic mechanism (abstract). Hepatology 16:126A, 1992CrossRefGoogle Scholar
  19. 19.
    Fisher B, Keenan AM, Garra BS, et al., Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 12:1852, 1989Google Scholar
  20. 20.
    Flynn RM, Palladino MA, TNF and TGF-β: the opposite sides of the avenue? In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging role in medicine. Raven, New York, pp. 131–144, 1992.Google Scholar
  21. 21.
    Frizell E, Degli-Esposti S, Manning P, et al., IL-1 receptor anatagonist therapy of hepatic fibrosis (abstract). Hepatology 16:182A, 1992Google Scholar
  22. 22.
    Fuji A, Kakumu S, Ohtani Y, et al., Interferon-gamma production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 7:577, 1987PubMedCrossRefGoogle Scholar
  23. 23.
    Gershenwald JE, Fong YM, Fahey TJ III, et al., Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 87:4966, 1990PubMedCrossRefGoogle Scholar
  24. 24.
    Ghezzi P, TNF and the liver. In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging role in medicine. Raven, New York, 1992Google Scholar
  25. 25.
    Henderson B, Blake S, Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 13:145, 1992PubMedCrossRefGoogle Scholar
  26. 26.
    Hirano T, Interleukin-6. In: Thomson A (ed) The cytokine handbook. Academic Press, New York, pp 169–190, 1992Google Scholar
  27. 27.
    Hunt NC, Goldin RD, Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol 14:146, 1992PubMedCrossRefGoogle Scholar
  28. 28.
    Khoruts A, Stahnke L, McClain CJ, et al., Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentration in chronic alcoholic patients. Hepatology 13:267, 1991PubMedCrossRefGoogle Scholar
  29. 29.
    Kohno T, Brewer MT, Baker SL, et al., A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331, 1990.PubMedCrossRefGoogle Scholar
  30. 30.
    Kovacs EJ, Fibrogenetic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 12:17, 1991.PubMedCrossRefGoogle Scholar
  31. 31.
    Lötscher H, Pan YE, Lahm H-W, et al., Molecular cloning and expression of the human 55kD tumor necrosis factor receptor. Cell 61:351, 1990.CrossRefGoogle Scholar
  32. 32.
    Mancine R, Jezequel AM, Marucci L, et al., Interleukin-1 receptor antagonist (IL-1Ra) reduces collagen deposition in experimental hepatic, fibrosis (abstract). J Hepatol 16 [Suppl 1]: S 32, 1992Google Scholar
  33. 33.
    Mori M, Yamaguchi H, Honda S, et al., Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51:6656, 1991PubMedGoogle Scholar
  34. 34.
    Müller C, Zielinski CC, Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis. J Hepatol 15:372, 1992PubMedCrossRefGoogle Scholar
  35. 35.
    Müller C, Knoflach P, Zielinski CC, Solube interleukin-2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 10:928, 1989PubMedCrossRefGoogle Scholar
  36. 36.
    Munoz C, Carlet J, Fitting C, et al., Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747, 1991PubMedGoogle Scholar
  37. 37.
    Nathan C, Nitric oxide as a secretory product of mammlian cells. FASEB J 6:3051, 1992PubMedGoogle Scholar
  38. 38.
    Nophar, Y, Kemper O, Brakebusch C, et al., Soluble forms of tumor necrosis factor receptor (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269, 1990PubMedGoogle Scholar
  39. 39.
    Nussler AK, Di Silvio M, Billiar R, et al., Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 176:261, 1992PubMedCrossRefGoogle Scholar
  40. 40.
    Oliff A, Defeo-Jones D, Boyer M, et al., Tumors secreting human TNF/cachectin induced cachexia in mice. Cell 50:555, 1987PubMedCrossRefGoogle Scholar
  41. 41.
    Peterson TC, Isbrucker RA, Fibroproliferation in liver disease: role of monocyte factors. Hepatology 15:191, 1992PubMedCrossRefGoogle Scholar
  42. 42.
    Porteu F, Brockhaus M, Wallach D, et al., Human neutrophil elastase releases a ligand-binding fragment from the 75-kD tumor necrosis factor (TNF) receptor. J Biol Chem 266:18 846, 1991.Google Scholar
  43. 43.
    Schall TJ, Lewis M, Koller KJ, et al., Molecular cloning and expression of a receptor for human necrosis factor. Cell 6:361, 1990CrossRefGoogle Scholar
  44. 44.
    Seckinger P, Isaaz S, Dayer J-M, a human inhibitor of tumor necrosis factor α. J Exp Med 168:1511, 1988CrossRefGoogle Scholar
  45. 45.
    Sherlock S, Dooley J, Diseases of the liver and biliary system. Blackwell, Oxford, 1993Google Scholar
  46. 46.
    Sheron N, Lau J, Daniels H, et al., Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 12:241, 1991PubMedCrossRefGoogle Scholar
  47. 47.
    Sherry BA, Gellin J, Fong Y, et al., Anticachectin/tumor necrosis factor-α antibodies, attenuate development of cachexia in tumor models. FASEB J 3:1956, 1989.PubMedGoogle Scholar
  48. 48.
    Shultz PJ, Raji L, Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 90:1718, 1992PubMedGoogle Scholar
  49. 49.
    Stark ME, Szurszewski JH, Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology 103:1928, 1992PubMedGoogle Scholar
  50. 50.
    Strassmann G, Fong M, Kenney JS, et al., Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 89:1681, 1992PubMedGoogle Scholar
  51. 51.
    Thomson A, The cytokine handbook. Academic Press, New York, 1992Google Scholar
  52. 52.
    Thornberry NA, Bull HG, Calaycay JR, et al., A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356:768, 1992PubMedCrossRefGoogle Scholar
  53. 53.
    Tilg H, Wilmer A, Vogel W, et al., Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264, 1992PubMedGoogle Scholar
  54. 54.
    Tilg H, Shapiro L, Atkins MB, et al., Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble TNF receptor p75-chimera. J Immunol (in press)Google Scholar
  55. 55.
    TilgeH, Vogel W, Wiedermann CJ, et al., Circulating IL-1 and TNF antagnoists in liver diseases. Heaptology (in press)Google Scholar
  56. 56.
    Thomas A, Soriano G, Guarner C, et al., Increased serum nitrite and nitrate in cirrhosis. Relationship to endotoxemia (abstract). J Hepatol 16 [Supp 1]: S 40, 1992Google Scholar
  57. 57.
    Toth CA, Thomas P, Liver endocytosis and Kupffer cells. Hepatology 16:255, 1992PubMedCrossRefGoogle Scholar
  58. 58.
    Tracey KJ, Wei H, Manogue KR, et al., Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 167:1211, 1988PubMedCrossRefGoogle Scholar
  59. 59.
    Tracey KJ, Morgello S, Koplin B, et al., Metabolic effects of chachectin/tumor necrosis factor are modified by site of production: cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 86:2014, 1990.PubMedCrossRefGoogle Scholar
  60. 60.
    Triger D, Wright R, Hyperglobulinaemia in liver disease. Lancet I:1494, 1973CrossRefGoogle Scholar
  61. 61.
    Vassalli P, The pathophysiology of tumor necrosis factors. Ann Rev Immunol 10:411, 1992CrossRefGoogle Scholar
  62. 62.
    Volpes R, Oord JJ van den, De Vos R, et al., Hepatic expression of type A and type B receptors for tumor necrosis factor. J Hepatol 14:361, 1992PubMedCrossRefGoogle Scholar
  63. 63.
    Wachter H, Fuchs D, Hausen D, et al., Neopterin as marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem 27:82, 1989Google Scholar
  64. 64.
    Whittle BJR, Moncada S, Nitric oxide: the elusive mediator of the hyperdynamic circulation of cirrhosis? Hepatology 16:1089, 1992PubMedCrossRefGoogle Scholar
  65. 65.
    Yokota M, Sakamato S, Koga S, et al., Decreased interleukin-1 activity in culture supernatent of lipopolysaccharide-stimulated monocytes from patients with liver cirrhosis and hepatocellular carcinoma. Clin Exp Immunol 67:335, 1987PubMedGoogle Scholar
  66. 66.
    Yoshioka K, Kakumu S, Arao M, et al., Tumor necrosis factor α production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 10:769, 1989PubMedCrossRefGoogle Scholar
  67. 67.
    Yoshioka K, Kakumu S, Arao M, et al., Immunohistochemical studies of intrahepatic tumour necrosis factor α in chronic liver disease. J Clin Pathol 43:298, 1990PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Herbert Tign
    • 1
  1. 1.Department of Medicine, Division of Gastroenterology-HepatologyUniversity Hospital InnsbruckInnsbruckAustria

Personalised recommendations